Drug Trial Radar · NCT01456936
Study Evaluating The Safety And Efficacy Of Varenicline and Bupropion For Smoking Cessation In Subjects With And Without A History Of Psychiatric Disorders
Last checked: Nov 19, 2026Latest source record: Jun 10, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,144
Actual
Start
Nov 2011
Primary completion
Jan 2015
Study completion Jan 2015
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Oct 21, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is being conducted to assess varenicline and bupropion as aids to smoking cessation treatment in subjects with and without an established diagnosis of major psychiatric disorder and to characterize the neuropsychiatric safety profile (pre-specified adverse events (AEs) in both of these populations).
Conditions
- Smoking Cessation
Interventions
PlaceboDrug
Triple dummy placebo for each treatment arm
varenicline tartrateDrug
Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks
bupropion hydrochlorideDrug
Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).
Nicotine Replacement Therapy PatchDrug
Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Neuropsychiatric (NPS) Adverse Events (AE) - the Primary Study EndpointTime frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
- Estimated NPS AE Rate (%), by CohortTime frame: Treatment emergent is first dose date to last dose date (up to 12 weeks) plus 30 days.
Locations
156 sites in 16 countries. Site status is shown where the registry gives one.
Coastal Clinical Research, Inc.
Mobile, Alabama
NoesisPharma Research
Phoenix, Arizona
Pharmacology Research Institute
Encino, California
Synergy Clinical Research of Escondido
Escondido, California
Sun Valley Research Center
Imperial, California
Omega Clinical Trials
La Habra, California
Pacific Treatment and Research Center UC San Diego Health System
La Jolla, California
Pharmacology Research Institute
Los Alamitos, California
David Geffen School of Medicine at University of California, Los Angeles
Los Angeles, California
Pharmacology Research Institute
Newport Beach, California
North County Clinical Research
Oceanside, California
Neuropsychiatric Research Center of Orange County
Orange, California
California Neuroscience Research Medical Group, Inc.
Sherman Oaks, California
University of Colorado Denver, Anschutz Medical Campus , Behavioral Health and Wellness Program
Aurora, Colorado
Western Affiliated Research Institute
Denver, Colorado
Comprehensive Psychiatric Care
Norwich, Connecticut
Neuropsychiatric Research Center of Southwest Florida
Fort Myers, Florida
Broward Research Group
Hollywood, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Mayo Clinic
Jacksonville, Florida
Clinical Neuroscience Solutions,Inc.
Jacksonville, Florida
Meridien Research
Lakeland, Florida
Renstar Medical Research
Ocala, Florida
Ocala Psychiatric Associates
Ocala, Florida
Clinical Neuroscience Solutions, Inc
Orlando, Florida
Meridien Research
Tampa, Florida
Northwest Behavioral Research Center
Marietta, Georgia
Clinical Research Atlanta
Stockbridge, Georgia
Advanced Clinical Research
Meridian, Idaho
Northwest Neurobehavioral Health
Meridian, Idaho
AMR-Baber Research Inc.
Naperville, Illinois
American Health Network of IN, LLC
Indianaopolis, Indiana
Davis Clinic, Incorporated
Indianapolis, Indiana
Goldpoint Clinical Research, LLC
Indianapolis, Indiana
Vince and Associates Clinical Research
Overland Park, Kansas
Heartland Research Associates, LLC
Wichita, Kansas
Central Kentucky Research Associates, Inc.
Lexington, Kentucky
Kentucky Research Group
Louisville, Kentucky
A Professional Corporation dba The Center for Sexual Health
Metairie, Louisiana
Maine Research Associates
Auburn, Maine
Showing 40 of 156 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.